Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    Gulf Shores, AL

    Search
    Gulf Shores, AL
    Show Map
    Map View
    Gulf Shores, AL
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      182 Clinical Trials near Gulf Shores, AL

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      BLU-5937 for Chronic Cough

      Gulf Shores, Alabama
      This trial is testing a medication called BLU-5937 to see if it can help reduce coughing in adults who have a persistent cough that doesn't get better with usual treatments. The study will measure how often participants cough over a period of several months after taking the medication.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Smoking, COPD, Asthma, Cancer, Others

      975 Participants Needed

      Depemokimab for Severe Asthma

      Gulf Shores, Alabama
      This trial is testing Depemokimab, a medication for people with severe asthma that doesn't respond well to usual treatments. It works by reducing specific cells that cause airway inflammation, aiming to improve breathing and reduce symptoms.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Malignancy, Uncontrolled Cardiovascular, Liver Disease, Others

      641 Participants Needed

      Tenapanor for Irritable Bowel Syndrome with Constipation

      Foley, Alabama
      This trial is testing a medication called tenapanor in children who have IBS-C. The medication helps to soften stools, making it easier to relieve constipation.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:12 - 17

      Key Eligibility Criteria

      Disqualifiers:Celiac Disease, Cystic Fibrosis, Hypothyroidism, Others
      Must Not Be Taking:Fiber Supplements, Anti-diarrheals

      180 Participants Needed

      Enlicitide + Rosuvastatin for High Cholesterol

      Foley, Alabama
      Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin. Rosuvastatin is a standard (usual) treatment to lower LDL-C. The goal of this study is to learn if enlicitide given with rosuvastatin works better than placebo on lowering LDL-C in a person's blood. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of a study medicine.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 64

      Key Eligibility Criteria

      Disqualifiers:Homozygous FH, Heart Failure, Myopathy, Others
      Must Be Taking:Statins

      975 Participants Needed

      AZD0780 for Cardiovascular Disease

      Foley, Alabama
      The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs placebo on the risk of MACE-PLUS will be evaluated from randomisation until the primary analysis censoring date (PACD). The Study Closure Visit will be scheduled to occur after the PACD and will be the final visit for each participant in the study.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Homozygous Familial Hypercholesterolaemia, Revascularisation Planned, Others
      Must Be Taking:Statins

      15100 Participants Needed

      Tezepelumab for COPD

      Foley, Alabama
      A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:40 - 80

      Key Eligibility Criteria

      Disqualifiers:Asthma, Tuberculosis, Malignancies, Others
      Must Be Taking:ICS, LABA, LAMA

      990 Participants Needed

      Enlicitide Decanoate for High Cholesterol

      Foley, Alabama
      This is an extension study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed either study MK-0616-013 (NCT05952856), study MK-0616-017 (NCT05952869), or study MK-0616-018 (NCT06450366).
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Serious Adverse Event, Others
      Must Not Be Taking:PCSK9 Inhibitors

      3000 Participants Needed

      AR882 for Gout

      Foley, Alabama
      This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Malignancy, Pregnant, Kidney Stones, Others

      750 Participants Needed

      MK-0616 for High Cholesterol

      Foley, Alabama
      This trial is testing MK-0616, a pill, in people with high cardiovascular risk. The goal is to see if it can prevent serious heart-related events by lowering bad cholesterol.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Heart Failure, Ventricular Tachycardia, Others
      Must Be Taking:Statins

      14550 Participants Needed

      Lorundrostat for High Blood Pressure

      Foley, Alabama
      This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypertension
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breast-feeding, Others
      Must Not Be Taking:Prohibited Medications

      1400 Participants Needed

      MK-0616 for High Cholesterol

      Foley, Alabama
      This trial is testing a new medication called MK-0616 to see if it can lower bad cholesterol levels in adults with high cholesterol. The study will compare the effects of MK-0616 over several months. The goal is to find out if MK-0616 is safe, effective, and well-tolerated.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Homozygous FH, Heart Failure, Others
      Must Be Taking:Statins

      2760 Participants Needed

      Tenapanor for Pediatric IBS with Constipation

      Foley, Alabama
      Open-label long-term safety study of tenapanor in pediatric patients with IBS-C.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3
      Age:6 - 18

      Key Eligibility Criteria

      Disqualifiers:Surgery On Stomach, Pregnant, Others

      150 Participants Needed

      Inclisiran for Cardiovascular Disease Prevention

      Foley, Alabama
      This trial tests whether inclisiran injections can prevent serious heart problems in high-risk adults who haven't had a major heart event yet by lowering their cholesterol levels. Inclisiran is a long-acting treatment that significantly lowers cholesterol.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:40 - 79

      Key Eligibility Criteria

      Disqualifiers:ASCVD, Revascularization, Liver Disease, Others
      Must Be Taking:Lipid Lowering

      14012 Participants Needed

      Linaclotide for Pediatric Constipation

      Foley, Alabama
      Functional constipation (FC) is a common healthcare problem in children of all ages, potentially due to genetic predisposition, inadequate fiber and fluid intake, and immobility. Currently, there are no pharmacological therapies approved for the treatment of FC. This study will assess adverse events and change in disease activity with linaclotide therapy in participants with FC. Linaclotide is an approved drug being developed for the treatment of FC in pediatric patients, ages 2 to 5, who meet modified Rome IV criteria for childhood FC. In Part 1 of this study, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. All participants in Part 2 will receive linaclotide. Approximately 116 participants aged 2 to 5 years with FC will be enrolled in this study at around 45 sites worldwide. Participants will receive daily doses of oral Linaclotide capsules or matching placebo for 12 weeks in Part 1 of the study. In Part 2, the open label long-term safety extension, participants with FC who completed study intervention in Part 1 of Study M21-572 or the Phase 2 Study LIN-MD-67 will receive linaclotide for 24 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:2 - 5

      Key Eligibility Criteria

      Disqualifiers:Celiac, Cystic Fibrosis, Hypothyroidism, Others

      123 Participants Needed

      Baxdrostat + Dapagliflozin for Chronic Kidney Disease

      Fairhope, Alabama
      The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin alone. Site visits will take place at 2-, 4-, 8-, and 16- weeks following randomisation. Thereafter visits will occur approximately every 4 months, until the 24-month visit at which time baxdrostat/placebo will be discontinued. Participants will continue open-label dapagliflozin for another 6-weeks (approximately), where reassessment of GFR will occur for the primary efficacy endpoint. In the event of premature discontinuation of blinded study intervention, participants will continue in the study and receive open-label dapagliflozin monotherapy, unless the participant meets dapagliflozin specific discontinuation criteria, in which case all study interventions will be discontinued.
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Diabetes, Heart Failure, Others
      Must Be Taking:ACE Inhibitors, ARBs

      2455 Participants Needed

      MK-7240 for Ulcerative Colitis

      Fairhope, Alabama
      This trial is testing tulisokibart, a new medication, to see if it can help people with moderately to severely active ulcerative colitis. The goal is to determine if tulisokibart can reduce inflammation and heal sores in the colon, leading to fewer symptoms. The study will compare different doses of tulisokibart over several months.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:16 - 80

      Key Eligibility Criteria

      Disqualifiers:Crohn's Disease, Fulminant Colitis, Cancer, Others

      1020 Participants Needed

      Asundexian for Stroke Prevention

      Fairhope, Alabama
      This trial is testing asundexian, a new medicine that prevents blood clots, in people who had a non-heart-related stroke or high-risk mini-stroke. The goal is to see if it works better at reducing future strokes without increasing bleeding risks. Asundexian is developed by Bayer AG and might prevent thrombosis without increasing bleeding.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Atrial Fibrillation, Mechanical Valve, Others
      Must Be Taking:Antiplatelets

      12327 Participants Needed

      Ziltivekimab for Heart Failure

      Fairhope, Alabama
      This trial is testing ziltivekimab to see if it can help people with heart failure and inflammation by reducing inflammation and improving heart function.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Recent MI, Stroke, Unstable Angina, Others

      5600 Participants Needed

      Tissue Kallikrein for Ischemic Stroke

      Fairhope, Alabama
      This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on participants with limited treatment options. Participants who have or will receive mechanical thrombectomy (MT) are not eligible for participation. Additionally, participants who have received fibrinolytics are excluded unless they experience a persistent neurological deficit of moderate severity six or more hours after fibrinolytic treatment. Participants considered for this trial should not be denied the use of standard of care (SoC) AIS therapies, such as fibrinolytics or MT, when appropriate. The double-blinded study will be randomized and placebo-controlled at up to approximately 100 sites.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Hemorrhagic Stroke, Large Vessel Occlusion, MT, HAE, Others
      Must Not Be Taking:ACE Inhibitors, HAE Treatments

      728 Participants Needed

      Hypoglossal Nerve Stimulation for Down Syndrome

      Norfolk, Virginia
      This study is a prospective, single-arm study conducted under a common implant and follow-up protocol. The objective will be to follow fifty-seven (57) adolescents and young adults (10-21 years of age), with Down syndrome, moderate to severe sleep apnea, and post-adenotonsillectomy, for 12 months after undergoing implant of the Inspire Upper Airway Stimulation (UAS) System. The study is being conducted in order to evaluate objective change in cognition and expressive language after implant and therapy with the Inspire UAS System.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:10 - 21

      Key Eligibility Criteria

      Disqualifiers:High BMI, Autism, Others
      Must Not Be Taking:Muscle Relaxants, NSAIDs

      57 Participants Needed

      Why Other Patients Applied

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40
      Match to a Trial

      Olpasiran for Cardiovascular Disease

      Fairhope, Alabama
      The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Prior Atherothrombotic Event, Revascularization, Bleeding Disorder

      11000 Participants Needed

      Maridebart Cafraglutide for Heart Failure

      Fairhope, Alabama
      This study will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part study with a double-blind period and an open-label extension (OLE). The study is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Severe Psychiatric, Others
      Must Be Taking:Standard HF Therapies

      5056 Participants Needed

      Maridebart Cafraglutide for Cardiovascular Disease

      Fairhope, Alabama
      The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:45 - 99

      Key Eligibility Criteria

      Disqualifiers:Recent MI, Type 1 DM, Others
      Must Not Be Taking:GLP-1 RAs, GIP Agonists

      12800 Participants Needed

      Baxdrostat + Dapagliflozin for Chronic Kidney Disease and High Blood Pressure

      Fairhope, Alabama
      International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:T1DM, Uncontrolled T2DM, Heart Failure, Others
      Must Be Taking:ACEi, ARB

      5000 Participants Needed

      Baxdrostat + Dapagliflozin for Heart Failure

      Fairhope, Alabama
      Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screening period to facilitate sites' identification of potentially eligible participants to enter the full screening assessments. Participants will not be required to visit the site and no informed consent is required for the optional pre-screening period. The pre-screening assessments do not replace the full screening tests at Visit 1. Upon entering the screening period, all consented participants (after signature of screening ICF) will be screened during an up to 14-day screening period. Participants who meet all screening inclusion/exclusion criteria but are not treated with SGLT2i or are treated for less than 4 weeks will enter a run-in period with dapagliflozin 10 mg once daily for at least 4 weeks (and not more than 6 weeks) before randomisation. Site visits will take place at approximately 2-, 4-, 8-, 16-, and 34-weeks following randomisation. Thereafter visits will occur approximately every 4 months. The study closure procedures will be initiated when the predetermined number of the first secondary endpoint events (ie, the composite of hospitalisation for HF or CV death) is predicted to have occurred i.e., the PACD. In case of premature discontinuation of the blinded study intervention, participants will remain in the study. Unless a participant meets the dapagliflozin specific discontinuation criteria, they will continue to receive open label dapagliflozin 10 mg. It is important that the scheduled study visits and data collection continue according to the study protocol.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:40+

      Key Eligibility Criteria

      Disqualifiers:Heart Failure, Severe Hepatic Impairment, Others
      Must Be Taking:SGLT2 Inhibitors

      11300 Participants Needed

      Ziltivekimab for Heart Attack

      Fairhope, Alabama
      The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant will need to inject the study medicine into a flat skin surface in there stomach, thigh, or upper arm once every month. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Chronic Heart Failure, Severe Kidney Impairment, Severe Hepatic Disease, Others

      10000 Participants Needed

      Finerenone for Heart Failure

      Fairhope, Alabama
      Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Low EGFR, Heart Transplant, Others
      Must Not Be Taking:Non-steroidal MRA, CYP3A4 Inhibitors

      2600 Participants Needed

      Finerenone + Empagliflozin for Heart Failure

      Fairhope, Alabama
      Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Severe Hyperkalemia, EGFR <30, Others
      Must Not Be Taking:MRA, SGLT2i, CYP3A4 Inhibitors

      1500 Participants Needed

      Pembrolizumab for Triple-Negative Breast Cancer

      Fairhope, Alabama
      The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Metastatic Cancer, Active Liver Disease, Others
      Must Be Taking:Pembrolizumab

      1295 Participants Needed

      High-Dose Radiation + Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

      Fairhope, Alabama
      This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Prior Radiotherapy, Pregnancy, Others

      474 Participants Needed

      12...7

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Popular Searches

      By Condition

      Depression Clinical Trials in Alabama

      Anxiety Clinical Trials in Alabama

      Schizophrenia Clinical Trials in Alabama

      ADHD Clinical Trials in Alabama

      Bipolar Disorder Clinical Trials in Alabama

      Multiple Sclerosis Clinical Trials in Alabama

      Autism Clinical Trials in Alabama

      Treatment Resistant Depression Clinical Trials in Alabama

      Borderline Personality Disorder Clinical Trials in Alabama

      Social Anxiety Disorder Clinical Trials in Alabama

      Parkinson's Disease Clinical Trials in Alabama

      Alzheimer's Disease Clinical Trials in Alabama

      By Location

      Clinical Trials near Birmingham, AL

      Clinical Trials near Mobile, AL

      Clinical Trials near Huntsville, AL

      Clinical Trials near Anniston, AL

      Clinical Trials near Dothan, AL

      Clinical Trials near Montgomery, AL

      Clinical Trials near Tuscaloosa, AL

      Clinical Trials near Homewood, AL

      Clinical Trials near Cullman, AL

      Clinical Trials near Muscle Shoals, AL

      Clinical Trials near Jasper, AL

      Clinical Trials near Sheffield, AL

      Other People Viewed

      By Subject

      Top Clinical Trials near Hoover, AL

      Top Clinical Trials near Jasper, AL

      Top Clinical Trials near Hueytown, AL

      Top Clinical Trials near Homewood, AL

      Top Clinical Trials near Guntersville, AL

      Top Clinical Trials near Foley, AL

      Top Clinical Trials near Dothan, AL

      Top Clinical Trials near Daphne, AL

      Top Clinical Trials near Cullman, AL

      Top Clinical Trials near Columbiana, AL

      Top Clinical Trials near Auburn, AL

      Top Clinical Trials near Andalusia, AL

      By Trial

      Ca-Mg Butyrate for Gulf War Syndrome

      Growth Hormone Replacement for Gulf War Illness

      Tai Chi + Wellness for Gulf War Syndrome

      Staccato Alprazolam for Rapid Onset

      nTMS for Brain Metastasis Planning

      Rilzabrutinib for Immune Thrombocytopenia

      Dietary Consultation for Obesity

      ARGX-119 for Congenital Myasthenic Syndromes

      Tolododekin Alfa + Cetrelimab for Non-Small Cell Lung Cancer

      IIMR vs CDSMP for Mental Health Disorders

      Lenvatinib for Adenoid Cystic Carcinoma

      CAD/CAM Endocrown for Nonvital Teeth

      Related Searches

      Top Clinical Trials near Gurnee, IL

      Top Clinical Trials near Hamden, CT

      Top Clinical Trials near Hammond, IN

      Defibrotide Prophylaxis + Stem Cell Transplant for Sickle Cell Disease

      iStent Infinite Device for Glaucoma

      Nivolumab + Cabozantinib for Kidney Cancer

      Oral Steroids for Osteoarthritis Pain

      Fatty Meal Challenge for Healthy Subjects

      Educational Letters for Neurofibromatosis

      Nutritional Support for Food Insecurity

      Fall Prevention Program for Multiple Sclerosis

      Cancer Vaccines for Lynch Syndrome

      Frequently Asked Questions

      How much do clinical trials in Gulf Shores, AL pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in Gulf Shores, AL work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Gulf Shores, AL 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Gulf Shores, AL is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Gulf Shores, AL several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in Gulf Shores, AL?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in Gulf Shores, AL?

      Most recently, we added Mirena for Endometrial Hyperplasia, Immune Globulin Infusion for Multiple Myeloma and Enlicitide + Rosuvastatin for High Cholesterol to the Power online platform.